Gilead Sciencesvs.Vertex Pharmaceuticals
GILD vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 1.3× larger than Vertex Pharmaceuticals by market cap; Gilead Sciences trades at the lower P/E (17.5 vs 27.9).
Side by side
| GILD | VRTX | |
|---|---|---|
| Market cap | $162B | $121B |
| Price | $129.83 | $485.39 |
| Today | −3.7% | −2.2% |
| Return YTD | +5.8% | +7.1% |
| Return 1Y | +13.3% | +1.2% |
| P/E | 17.5 | 27.9 |
| P/S | 5.4 | 9.9 |
| P/B | 6.9 | 6.3 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →Vertex PharmaceuticalsVRTX
American biotech company and global leader in cystic fibrosis treatment, with a pipeline in pain and gene therapy.
Full VRTX profile →More comparisons in Biotech & innovation
See where GILD and VRTX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →